<DOC>
	<DOC>NCT00147498</DOC>
	<brief_summary>The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).</brief_summary>
	<brief_title>Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The subject has a history of inadequate response to at least 1, but no more than 4, of the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide, cyclosporine, or a thiopurine derivative (azathioprine or 6mercaptopurine) Current Therapy With Any DMARD Or Biologic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>oral JAK inhibitor</keyword>
	<keyword>clinical trial</keyword>
	<keyword>joint diseases</keyword>
	<keyword>anti-Inflammatory agents</keyword>
	<keyword>rheumatic diseases</keyword>
	<keyword>DMARD</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>